An innovative dual action (antimicrobial & immunomodulator) product for the aquaculture feed additives market

Projektinformationen

AQUAGARLIC

ID Finanzhilfevereinbarung: 887860

DOI

10.3030/887860

Projekt abgeschlossen

EK-Unterschriftsdatum 31 Oktober 2019

Startdatum 1 November 2019

Enddatum 29 Februar 2020

Finanziert unter

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Gesamtkosten

€ 71 429,00

EU-Beitrag

€ 50 000,00

Koordiniert durch

DOMCA SA
Spain

Periodic Reporting for period 1 - AQUAGARLIC (An innovative dual action (antimicrobial & immunomodulator) product for the aquaculture feed additives market)

Berichtszeitraum: 2019-11-01 bis 2020-02-29

Zusammenfassung vom Kontext und den Gesamtzielen des Projekts

Aquacultured fish diseases are a clear indicator of the presence of pathogens (normally microbes and/or parasites). These pathogens can cause health problems to humans when eating the infected fish. Beside this, loss of yield in aquaculture production can rise up to 50% due to this situation. At Domca, we aim to meet the needs of our customers, expanding our sales portfolio while we enter a market of € 1.05 billion (CAGR of 3.2%), offering a new and natural-based revolutionary solution for the protection against parasites and microbes: AQUAgarlic. The objective of this project, AQUAgarlic, is to finish the development phase for the launching of Domca’s new product in the aquaculture market, with the first dual action (antimicrobial and immunomodulator) feed additive for aquaculture industry based on organosulfur natural active ingredients, with zero residues, effective and environmentally friendly. This product would be a game changer, as most related products (synthetic medicines) are not environmentally friendly and are targeted to only one specific threat (microbe or parasite).

Arbeit, die ab Beginn des Projekts bis zum Ende des durch den Bericht erfassten Berichtszeitraums geleistet wurde, und die wichtigsten bis dahin erzielten Ergebnisse

With this feasibility study we have been able to verify the technical and economic viability of the AQUAgarlic project and we have decided to continue with our business idea. The next step will be to prepare a Phase 2 proposal in order to get the necessary funding for the industrial scale-up of our innovation. We have identified the necessary activities for the next phase 2 project as well as the required resources, and we have confirmed that these are feasible in a reasonable time frame of two years, allowing us to start commercializing our product by Q4 2021 / Q1 2022, according to the business plan defined in this document.

Fortschritte, die über den aktuellen Stand der Technik hinausgehen und voraussichtliche potenzielle Auswirkungen (einschließlich der bis dato erzielten sozioökonomischen Auswirkungen und weiter gefassten gesellschaftlichen Auswirkungen des Projekts)

Domca will introduce a turnkey solution in the market that offers clear commercial and technical advantages when compared to the technology currently used in the different industrial sectors where it can be applied:
• Natural food additive for aquaculture, the key active ingredients for this product are extracts from Alliaceae (revaluation of raw agricultural by-products).
• Dose dependent dual action: broad spectrum antimicrobial action, since they attack a large number of pathogenic bacteria that cause infections (gram-positive as gram-negative) and destroy and inhibit parasitic growth.
• Regulate immune system, by increasing or decreasing the ability to produce antibodies.
• Zero residues, eliminating the environmental, animals and human health impact.
• No fish withdrawal time.
• It is a stable product with high thermal and pressure resistance.

AQUAGARLIC LOGO